Centro de Estudios Clínicos SAGA

The trials here

What the 10 trials at this site are about, from their registry records.

Conditions

• Lung cancer3 trials
• Bladder cancer1 trial
• Colorectal cancer1 trial
• Diffuse large B-cell lymphoma1 trial
• Endometrial cancer1 trial
• Gastric and oesophageal cancer1 trial
• Head and neck cancer1 trial
• Liver and biliary tract cancer1 trial
• Metastatic breast cancer1 trial
• Prostate cancer1 trial

Phase

• Phase 38 trials
• Phase 2/31 trial

Status

• Recruiting4 trials
• Active, not recruiting3 trials
• Completed3 trials

Lead sponsor

• Daiichi Sankyo3 trials
• Hoffmann-La Roche2 trials
• ADC Therapeutics S.A.1 trial
• BioNTech SE1 trial
• Pfizer1 trial
• and 2 more

Running trials

• Recruiting

  A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting

  NCT07022483· Phase 3· Daiichi Sankyo· Source

• Recruiting

  Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

  NCT06731478· Phase 3· Daiichi Sankyo· Source

• Recruiting

  A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

  NCT06629779· Phase 3· Pfizer· Source

• Recruiting

  A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

  NCT05253651· Phase 3· Seagen, a wholly owned subsidiary of Pfizer· Source

• Active, not recruiting

  Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations

  NCT05215340· Phase 3· Daiichi Sankyo· Source

• Active, not recruiting

  A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1

  NCT04534205· Phase 2/3· BioNTech SE· Source

• Active, not recruiting

  Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

  NCT04384484· Phase 3· ADC Therapeutics S.A.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Colorectal cancer1 recruiting
• Endometrial cancer1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Prostate cancer1 recruiting

Closed trials

• Completed

  Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)

  NCT05153239· Phase 3· PharmaMar· Source

• Completed

  A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer

  NCT05415215· Phase 3· Hoffmann-La Roche· Source

• Completed

  A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice

  NCT03782207· Hoffmann-La Roche· Source